Novel therapeutic agents with combined actions on AQP1 ion channel inhibition and HbS stabilization could offer the desired slowing of dehydration and HbS polymerization, a goal of international interest for expanding the range of affordable clinical options for treating sickle cell disease. The gene discussed is AQP1; the disease is sickle cell disease.